Aditya Bardia
Harvard University · 1,252 works · 41,023 citations · h-index 90
Top works
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
- Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
- Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
- Hand-Foot Syndrome After Dose-Dense Adjuvant Chemotherapy for Breast Cancer: A Case Series
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
- Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells
- Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
- Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer
- Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
- Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis
- A microfluidic device for label-free, physical capture of circulating tumor cell clusters
- LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- Ribociclib plus Endocrine Therapy in Early Breast Cancer
- Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
- Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial